Fig. 3
Structures underlying the most common PROTACs: VHL inhibitors, MDM2 inhibitors, CRBN ligands, IAP antagonists (A); examples of PROTACs in clinical trials (B)
Fig. 3 | Biology Direct
Structures underlying the most common PROTACs: VHL inhibitors, MDM2 inhibitors, CRBN ligands, IAP antagonists (A); examples of PROTACs in clinical trials (B)